Rejection versus escape: the tumor MHC dilemma

[1]  F. Garrido,et al.  The absence of HLA class I expression in non‐small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration , 2017, International journal of cancer.

[2]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[3]  F. Garrido,et al.  Targetless T cells in cancer immunotherapy , 2016, Journal of Immunotherapy for Cancer.

[4]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[5]  F. Garrido,et al.  The urgent need to recover MHC class I in cancers for effective immunotherapy , 2016, Current opinion in immunology.

[6]  M. Donia,et al.  Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen , 2016, Clinical Cancer Research.

[7]  F. Garrido,et al.  Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype , 2016, International journal of cancer.

[8]  T. Illidge,et al.  Immuno-regulatory antibodies for the treatment of cancer , 2015, Expert opinion on biological therapy.

[9]  A. Epstein,et al.  MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro , 2014, Clinical Cancer Research.

[10]  F. Garrido,et al.  Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition , 2014, Cancer Gene Therapy.

[11]  Ryan Emerson,et al.  CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.

[12]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[13]  A. Cerwenka,et al.  Shaping of NK Cell Responses by the Tumor Microenvironment , 2013, Cancer Microenvironment.

[14]  J. Kirkwood,et al.  IFN-α in the Treatment of Melanoma , 2012, The Journal of Immunology.

[15]  A. Concha,et al.  Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes , 2012, Cancer Immunology, Immunotherapy.

[16]  Federico Garrido,et al.  Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon‐mediated rejection genes , 2012, International journal of cancer.

[17]  L. Ramakrishnan.  Revisiting the role of the granuloma in tuberculosis , 2012, Nature Reviews Immunology.

[18]  M. Kloor,et al.  Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial , 2012, British Journal of Cancer.

[19]  F. Garrido,et al.  Bacillus Calmette‐Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I‐deficient tumor cells , 2011, International journal of cancer.

[20]  P. Coulie,et al.  Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. , 2011, Cancer research.

[21]  F. Garrido,et al.  “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy , 2010, International journal of cancer.

[22]  S. Mukhopadhyay,et al.  Granulomatous lung disease: an approach to the differential diagnosis. , 2010, Archives of pathology & laboratory medicine.

[23]  F. Garrido,et al.  Efficient Recovery of HLA Class I Expression in Human Tumor Cells After Beta2‐Microglobulin Gene Transfer Using Adenoviral Vector: Implications for Cancer Immunotherapy , 2009, Scandinavian journal of immunology.

[24]  B. Seliger,et al.  Chapter 7 IFN Inducibility of Major Histocompatibility Antigens in Tumors , 2008, Advances in Cancer Research.

[25]  F. Garrido,et al.  Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy , 2008, Immunogenetics.

[26]  M. Nishimura,et al.  HLA class I antigen expression is associated with a favorable prognosis in early stage non‐small cell lung cancer , 2007, Cancer science.

[27]  F. Garrido,et al.  Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines , 2007, BMC Cancer.

[28]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[29]  Thierry Boon,et al.  Human T cell responses against melanoma. , 2006, Annual review of immunology.

[30]  M. Kloor,et al.  Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. , 2005, Cancer research.

[31]  M. Büchler,et al.  Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  F. Garrido,et al.  Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 , 2004, Immunogenetics.

[33]  J. Tímár,et al.  T-Cell Activation Marker Expression on Tumor-Infiltrating Lymphocytes As Prognostic Factor in Cutaneous Malignant Melanoma , 2004, Clinical Cancer Research.

[34]  F. Garrido,et al.  MHC class I‐deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components , 2003, International journal of cancer.

[35]  B. Seliger,et al.  HLA class I antigen abnormalities and immune escape by malignant cells. , 2002, Seminars in cancer biology.

[36]  F. Garrido,et al.  A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line , 2001, Immunogenetics.

[37]  P. Schlag,et al.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.

[38]  P. Stern,et al.  A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells , 2000, Immunogenetics.

[39]  G. Fleuren,et al.  Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer , 2000, The Journal of experimental medicine.

[40]  F. Garrido,et al.  Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors , 1999, International journal of cancer.

[41]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[42]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[43]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[44]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[45]  J. Bodmer,et al.  Mechanisms of loss of HLA class I expression on colorectal tumor cells. , 1996, Tissue antigens.

[46]  P. Stern,et al.  Natural history of HLA expression during tumour development. , 1993, Immunology today.

[47]  J. Bodmer,et al.  Tumor Escape from Immune Response by Variation in HLA Expression and Other Mechanisms , 1993, Annals of the New York Academy of Sciences.

[48]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[49]  J. Davey,et al.  Cytotoxic T cells recognize fragments of the influenza nucleoprotein , 1985, Cell.

[50]  J. Hors,et al.  HLA and cancer. , 1984, Transplantation proceedings.

[51]  A. Morales,et al.  INTRACAVITARY BACILLUS CALMETTE‐GUERIN IN THE TREATMENT OF SUPERFICIAL BLADDER TUMORS , 1976, The Journal of urology.

[52]  M. A. Basombrío.  Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. , 1970, Cancer research.

[53]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[54]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[55]  R. W. Baldwin.  Immunity to Methylcholanthrene-Induced Tumours in Inbred Rats Following Atrophy and Regression of the Implanted Tumours , 1955, British Journal of Cancer.

[56]  Baldwin Rw.  Immunity to Methylcholanthrene-Induced Tumours in Inbred Rats Following Atrophy and Regression of the Implanted Tumours , 1955 .

[57]  Foley Ej.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953 .

[58]  P. Gorer.  The genetic and antigenic basis of tumour transplantation , 1937 .

[59]  S. Aamdal,et al.  Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma , 2014, International journal of cancer.

[60]  P. Romero,et al.  Adaptive T-cell immunity and tumor antigen recognition , 2014 .

[61]  F. Garrido,et al.  Role of altered expression of HLA class I molecules in cancer progression. , 2007, Advances in experimental medicine and biology.

[62]  D. Schadendorf,et al.  Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy , 2006, Cancer Immunology, Immunotherapy.

[63]  F. Garrido,et al.  Analysis of HLA expression in human tumor tissues , 2002, Cancer Immunology, Immunotherapy.

[64]  F. Garrido,et al.  Immunoselection by T lymphocytes generates repeated MHC class I‐deficient metastatic tumor variants , 2001, International Journal of Cancer.

[65]  F. Garrido,et al.  MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.

[66]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[67]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.

[68]  E. J. Foley.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953, Cancer research.